Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

NCT01208103 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01208103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01208103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 6, 2011
Completion date
March 7, 2018
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ampulla of vater adenocarcinoma, small intestinal adenocarcinoma, stage iii ampulla of vater cancer ajcc v8, stage iii small intestinal adenocarcinoma ajcc v8, stage iiia ampulla of vater cancer ajcc v8, stage iiia small intestinal adenocarcinoma ajcc v8, stage iiib ampulla of vater cancer ajcc v8, stage iiib small intestinal adenocarcinoma ajcc v8, stage iv ampulla of vater cancer ajcc v8, stage iv small intestinal adenocarcinoma ajcc v8